Human medicines European public assessment report (EPAR): Trumenba, meningococcal group b vaccine (recombinant, adsorbed), Date of authorisation: 24/05/2017, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Noxafil, posaconazole, Date of authorisation: 25/10/2005, Revision: 42, Status: Authorised

Human medicines European public assessment report (EPAR): Aspaveli, pegcetacoplan, Date of authorisation: 13/12/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): TachoSil, human fibrinogen,human thrombin, Date of authorisation: 08/06/2004, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Arexvy, recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E, Date of authorisation: 06/06/2023, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Xevudy, sotrovimab, Date of authorisation: 17/12/2021, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Lumeblue (previously Methylthioninium chloride Cosmo), methylthioninium chloride, Date of authorisation: 19/08/2020, Revision: 5, Status: Authorised

Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence - Scientific guideline

Outcome of public consultation on the reflection paper use of real-world data in non-interventional studies to generate real-world evidence for regulatory purposes - Summary report of comments received during the public consultation and next steps

Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence for regulatory purposes